Disease Areas
Diabetes
Obesity
Cardiovascular Disease (CVD)
Chronic Kidney Disease (CKD)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Neurodegenerative Diseases
Haemophilia
Sickle Cell Disease
Primary Hyperoxaluria
Growth Hormone Disorders
Hormone Replacement Therapy
Congresses
Scientific Publications
IME
Search Science Hub
Register
Login
My Account
Welcome to Novo Nordisk Science Hub
Are you a healthcare professional?
No
Yes
Congresses
EASD 2025
Oral semaglutide and cardiovascular outcomes by baseline A1c and BMI in people with type 2 diabetes in the SOUL trial
EASD 2025
EASD 2025
15 - 19 September 2025
Oral semaglutide and cardiovascular outcomes by baseline A1c and BMI in people with type 2 diabetes in the SOUL trial
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Share
Copy link
{{pageUrl}}
Keywords
Diabetes
Congress oral presentation
GLP-1 RA
Semaglutide (oral)
PHASE 3 (RCT)
